Home › Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab
 

Keywords :   


Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab

2016-07-21 22:30:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today said that the U.S. Food and Drug Administration (FDA) has requested the submission of new data and analyses from the MODIFY I and MODIFY II clinical trials previously submitted to the pending Biologics Licensing Application (BLA) for bezlotoxumab, an investigational agent for prevention of Clostridium difficile (C. difficile) infection recurrence. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Robert Consalvo, 908-236-1127orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: application update agent regulatory

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
28.06Cattle producers celebrate Supreme Court decision to rein in administrative overreach
28.06Diversified Labeling Solutions expands RFID capabilities
28.06Eastern North Pacific Tropical Weather Outlook
28.06Atlantic Tropical Weather Outlook
28.06Commitment leads to success in cattle marketing
28.06Kurz opens new facility in Germany
28.06Apex invests in Schepers laser engraving technology
28.06All4Labels opens first factory in Northeast Brazil
More »